Enkephalin derivative, cyclo[Nε,Nβ-carbonyl-d-Lys2, Dap5] enkephalinamide (cUENK6), induces a highly potent antinociception in rats

Neuropeptides

Volumn 43, Issue 3, 2009, Pages 221-228

  Kotlinska, Jolanta ^a   Bochenski, Marcin ^a   Lagowska Lenard, Monika ^a   Gibula Bruzda, Ewa ^a   Witkowska, Ewa ^b   Izdebski, Jan ^b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b UNIVERSITY OF WARSAW   (Poland)

Author keywords

Cross tolerance; cUENK6; Hot plate; Locomotor activity; Morphine; Nociception; Tail immersion

Indexed keywords

BETA FUNALTREXAMINE; CYCLO[N EPSILON,N BETA CARBONYL 2 DEXTRO LYSINE,5 ALPHA,BETA DIAMINOPROPANOIC ACID]ENKEPHALINAMIDE; DELTA OPIATE RECEPTOR; ENKEPHALIN DERIVATIVE; KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; NALTRINDOLE; NORBINALTORPHIMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; EXPERIMENTAL TEST; HOT PLATE TEST; LATENT PERIOD; LOCOMOTION; MALE; MORPHINE TOLERANCE; NOCICEPTIVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; RAT; STIMULUS RESPONSE; TAIL IMMERSION TEST;

ANALGESICS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; ENKEPHALINS; MORPHINE; PAIN; RATS; RECEPTORS, OPIOID;

CAVIA; RATTUS;

EID: 67349286252     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2009.03.003     Document Type: Article

References (53)

1. Babbini M., and Davis W.M. Time-dose relationships for locomotor activity effects of morphine after acute or repeated treatment. Br. J. Pharmacol. 46 (1972) 213-224
2. Belluzzi J.D., Grant N., Garsky V., Sarantakis D., Wise C.D., and Stein L. Analgesia induced in vivo by central administration of enkephalin in rat. Nature 260 (1976) 625-626
3. Benthuysen J.L., Hance A.J., Quam D.D., and Winters W.D. Synthetic opioids compared with morphine and ketamine: catalepsy, cross-tolerance and interactions in the rat. Neuropharmacology 28 (1989) 1011-1015
4. Burks T.F., Fox D.A., Hirning L.D., Shook J.E., and Porreca F. Regulation of gastrointestinal function by multiple opioid receptors. Life Sci. 43 (1988) 2177-2181
5. Buxbaum D.M., Yarbrough G.G., and Carter M.E. Biogenic amines and narcotic effects. I. Modification of morphine-induced analgesia and motor activity after alteration of cerebral amine levels. J. Pharmacol. Exp. Ther. 185 (1973) 317-327
6. Cheng P.Y., Wu D., Soong Y., McCabe S., Decena J.A., and Szeto H.H. Role of mu 1- and delta-opioid receptors in modulation of fetal EEG and respiratory activity. Am. J. Physiol. 265 (1993) 433-438
7. Cowan A., Zhu X.Z., Mosberg H.I., Omnaas J.R., and Porreca F. Direct dependence studies in rats with agents selective for different types of opioid receptor. J. Pharmacol. Exp. Ther. 246 (1988) 950-955
8. Delfs J.M., Kong H., Mestek A., Chen Y., Yu L., Reisine T., and Chesselet M.F. Expression of mu opioid receptor mRNA in rat brain: an in situ hybridization study at the single cell level. J. Comp. Neurol. 345 (1994) 46-68
9. Dickenson A.H. Plasticity: implications for opioid and other pharmacological interventions in specific pain states. Behav. Brain Sci. 20 (1997) 392-403
10. Gutkowska J., Jankowski M., Pawlak D., Mukaddam-Daher S., and Izdebski J. The cardiovascular and renal effects of a highly potent mu-opioid receptor agonist, cyclo[N epsilon, N beta-carbonyl-d-Lys2, Dap5]enkephalinamide. Eur. J. Pharmacol. 496 (2004) 167-174
11. Hayes A.G., Skingle M., and Tyers M.B. Effect of beta-funaltrexamine on opioid side-effects produced by morphine and U-50, 488H. J. Pharm. Pharmacol. 37 (1985) 841-843
12. In: Herz A. (Ed). Opioids I (1993), Springer-Verlag, New York
13. Heyman J.S., Vaught J.L., Mosberg H.I., Haaseth R.C., and Porreca F. Modulation of mu-mediated antinociception by delta agonists in the mouse: selective potentiation of morphine and normorphine by [d-Pen2, d-Pen5]enkephalin. Eur. J. Pharmacol. 165 (1989) 1-10
14. Hughes J., Smith T.W., Kosterlitz H.W., Fothergill L.A., Morgan B.A., and Morris H.R. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 258 (1975) 577-580
15. Irwin S., Bennett D.R., Hendershot L.C., Seevers M.H., and Hude R. The effects of morphine, methadone and meperidine on some reflex responses of spinal animals to nociceptive stimulation. J. Pharm. Exp. Ther. 101 (1951) 132-143
16. Jaffe J.M., and Martin W.R. Opioid analgesics and antagonist. In: Gilman A., Rall J., Nies A., and Taylor P. (Eds). The Pharmacological Basis of Therapeutics (1990), Pergamon Press, New York 485-573
17. Janssen P.A., Niemegeers C.J.E., and Dony J.G.H. The inhibitory effect of fentanyl and other morphine-like analgesics on the warm water induced tail withdrawal reflex in rats. Arzneim.-Forsch. 13 (1963) 502-507
18. Jensen T.S., and Yaksh T.L. Comparison of antinociceptive action of morphine in the periaqueductal gray, medial and paramedial medulla in rat. Brain Res. 363 (1986) 99-113
19. Kalivas P.W., and Abhold R. Enkephalin release into the ventral tegmental area in response to stress: modulation of mesocorticolimbic dopamine. Brain Res. 414 (1987) 339-348
20. Kotlinska J. Are glycineB sites involved in the development of morphine tolerance?. Pol. J. Pharmacol. 56 (2004) 51-57
21. Kuribara H. Modification of morphine sensitization by opioid and dopamine receptor antagonists: evaluation by studying ambulation in mice. Eur. J. Pharmacol. 275 (1995) 251-258
22. Latimer L.G., Duffy P., and Kalivas P.W. Mu opioid receptor involvement in enkephalin activation of dopamine neurons in the ventral tegmental area. J. Pharmacol. Exp. Ther. 241 (1987) 328-337
23. Le Bars D., Gozariu M., and Cadden S.W. Animal models of nociception. Pharmacol. Rev. 53 (2001) 597-652
24. Ling G.S., MacLeod J.M., Lee S., Lockhart S.H., and Pasternak G.W. Separation of morphine analgesia from physical dependence. Science 226 (1984) 462-464
25. Malmberg A.B., and Yaksh T.L. Isobolographic and dose-response analyses of the interaction between intrathecal mu and delta agonists: effects of naltrindole and its benzofuran analog (NTB). J. Pharmacol. Exp. Ther. 263 (1992) 264-275
26. Mansour A., Fox C.A., Akil H., and Watson S.J. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 18 (1995) 22-29
27. Mansour A., Khachaturian H., Lewis M.E., Akil H., and Watson S.J. Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J. Neurosci. 7 (1987) 2445-2464
28. Matthes H.W., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., Le Meur M., Dollé P., Tzavara E., Hanoune J., Roques B.P., and Kieffer B.L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383 (1996) 819-823
29. Meyer M.E., and Meyer M.E. Behavioral effects of the mu-opioid peptide agonists DAMGO, DALDA, and PL017 on locomotor activities. Pharmacol. Biochem. Behav. 46 (1993) 391-395
30. Meyer M.E., and Meyer M.E. Behavioral effects of opioid peptide agonists DAMGO, DPDPE, and DAKLI on locomotor activities. Pharmacol. Biochem. Behav. 45 (1993) 315-320
31. 2), a potent mu-opioid peptide agonist, affects various patterns of locomotor activities. Pharmacol. Biochem. Behav. 51 (1995) 149-151
32. Moskowitz A.S., and Goodman R.R. Light microscopic autoradiographic localization of mu and delta opioid binding sites in the mouse central nervous system. J. Neurosci. 4 (1984) 1331-1342
33. Nath C., Patnaik G.K., Haq W., Mathur K.B., Srimal R.C., Dhawan B.N., and Porreca F. Novel met-enkephalin analogue: a potent systemic mu agonist antinociceptive agent. Pharmacol. Res. 31 (1995) 269-273
34. Pasternak G.W., Simantov R., and Snyder S.H. Characterization of an endogenous morphine-like factor(enkephalin) in mammalian brain. Mol. Pharmacol. 12 (1976) 504-513
35. Pawlak D., Oleszczuk M., Wojcik J., Pachulska M., Chung N.N., Schiller P.W., and Izdebski J. Highly potent side-chain to side-chain cyclized enkephalin analogues containing a carbonyl bridge: synthesis, biology and conformation. J. Pept. Sci. 7 (2001) 128-140
36. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. fifth ed. (2005), Elsevier Academic Press, Amsterdam
37. Pleuvry B.J. Update on opioids. Curr. Anaesth. Crit. Care 14 (2003) 155-159
38. Porreca F., Takemori A.E., Sultana M., Portoghese P.S., Bowen W.D., and Mosberg H.I. Modulation of mu-mediated antinociception in the mouse involves opioid delta-2 receptors. J. Pharmacol. Exp. Ther. 263 (1992) 147-152
39. Portoghese P.S., Sultana M., and Takemori A.E. Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist. Eur. J. Pharmacol. 146 (1988) 185-186
40. Schad C.A., Justice Jr. J.B., and Holtzman S.G. Differential effects of delta- and mu-opioid receptor antagonists on the amphetamine-induced increase in extracellular dopamine in striatum and nucleus accumbens. J. Neurochem. 67 (1996) 2292-2299
41. Scherrer G., Befort K., Contet C., Becker J., Matifas A., and Kieffer B.L. The delta agonists DPDPE and deltorphin II recruit predominantly mu receptors to produce thermal analgesia: a parallel study of mu, delta and combinatorial opioid receptor knockout mice. Eur. J. Neurosci. 19 (2004) 2239-2248
42. Sheldon R.J., Rivière P.J., Malarchik M.E., Moseberg H.I., Burks T.F., and Porreca F. Opioid regulation of mucosal ion transport in the mouse isolated jejunum. J. Pharmacol. Exp. Ther. 253 (1990) 144-151
43. Simon E.J. Opioid receptors and endogenous opioid peptides. Med. Res. Rev. 11 (1991) 357-374
44. Su Y.F., McNutt R.W., and Chang K.J. Delta-opioid ligands reverse alfentanil-induced respiratory depression but not antinociception. J. Pharmacol. Exp. Ther. 287 (1998) 815-823
45. Svingos A.L., Clarke C.L., and Pickel V.M. Localization of the delta-opioid receptor and dopamine transporter in the nucleus accumbens shell: implications for opiate and psychostimulant cross-sensitization. Synapse 34 (1999) 1-10
46. Takemori A.E., Ho B.Y., Naeseth J.S., and Portoghese P.S. Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J. Pharmacol. Exp. Ther. 246 (1988) 255-258
47. Traynor J.R., and Elliott J. δ-Opioid receptor subtypes and cross-talk with μ-receptors. Trends Pharmacol. Sci. 14 (1993) 84-86
48. Vaught J.L., and Takemori A.E. Characterization of leucine and methionine enkephalin and their interaction with morphine on the guinea pig ileal longitudinal muscle. Res. Commun. Chem. Pathol. Pharmacol. 21 (1978) 391-407
49. Vaught J.L., and Takemori A.E. Characterization of leucine and methionine enkephalin and their interaction with morphine on the guinea pig ileal longitudinal muscle. Res. Commun. Chem. Pathol. Pharmacol. 21 (1978) 391-407
50. Vezina P., Kalivas P.W., and Stewart J. Sensitization occurs to the locomotor effects of morphine and the specific mu opioid receptor agonist, DAGO, administered repeatedly to the ventral tegmental area but not to the nucleus accumbens. Brain Res. 417 (1987) 51-58
51. Ward S.J., and Takemori A.E. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice. J. Pharmacol. Exp. Ther. 224 (1983) 525-530
52. Winkler M., Havemann U., and Kuschinsky K. Unilateral injection of morphine into the nucleus accumbens induces akinesia and catalepsy, but no spontaneous muscular rigidity in rats. Naunyn Schmiedebergs Arch. Pharmacol. 318 (1982) 143-147
53. Zadina J.E., Hackler L., Ge L.J., and Kastin A.J. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386 (1997) 499-502